← All companies
BMY
BRISTOL MYERS SQUIBB CO · Health Care
8 quarters · 66 figures · latest Q3 FY2026 filed 2026-10-29 →
Compared
6 of 8 · select any line below to add or remove it ·
Total Revenues
$13.07bn+6.9% Y/YQ3 FY2026
Net Earnings/(Loss)
$2.16bn−1.5% Y/YQ3 FY2026
Earnings/(Loss) per Common Share - Diluted
$1.05−2.8% Y/YQ3 FY2026
Gross margin
68.3%−5.0% Y/YQ3 FY2026
Amortization of acquired intangible assets
$458m−44.9% Y/YQ3 FY2026
Cost of products sold
$4.15bn+20.7% Y/YQ3 FY2026
Reported figures
Click any line for its full history. Each figure links to the filing it was read from.
Income statement
36 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Amortization of acquired intangible assetsamortization_acquired_intangibles | $826m | $437m | $437m | $458m | −44.9% | +4.8% | |
| Cost of products soldcost_of_products_sold | $4.1bn | $3.42bn | $3.73bn | $4.15bn | +20.7% | +11.3% | |
| Earnings/(Loss) per Common Share - Basiceps_basic | $0.53 | $1.31 | $1.62 | $1.06 | −1.9% | −34.6% | |
| Earnings/(Loss) per Common Share - Dilutedeps_diluted | $0.53 | $1.31 | $1.62 | $1.05 | −2.8% | −35.2% | |
| Earnings/(Loss) Per Share - Non-GAAPeps_diluted_non_gaap | $1.26 | $1.58 | $2.04 | $1.35 | −17.2% | −33.8% | |
| Income tax provisionincome_tax_provision | $384m | $561m | $770m | $374m | −59.3% | −51.4% | |
| Net Earnings/(Loss) Attributable to BMSnet_income_attributable | $1.09bn | $2.68bn | $3.32bn | $2.16bn | −1.8% | −34.8% | |
| Net earnings/(loss) attributable to BMS used for diluted EPS calculation (Non-GAAP)net_income_attributable_non_gaap | $2.57bn | $3.24bn | $4.17bn | $2.77bn | −16.6% | −33.7% | |
| Net product salesnet_product_sales | $12.11bn | $11.17bn | $12.59bn | $12.61bn | +6.4% | +0.1% | |
| Other (income)/expense, netother_income_expense_net | −$51m | $32m | −$61m | $307m | +384.3% | +603.3% | |
| Earnings/(Loss) Before Income Taxespretax_income | $1.47bn | $3.24bn | $4.09bn | $2.54bn | −18.6% | −37.9% | |
| Total Expensestotal_expenses | $11.03bn | $8.25bn | $8.89bn | $10.53bn | +15.6% | +18.5% | |
| Total Revenuestotal_revenue | $12.5bn | $11.49bn | $12.97bn | $13.07bn | +6.9% | +0.7% | |
| Acquired IPRDacquired_iprd | $1.39bn | $94m | — | $1.56bn | +146.1% | — | |
| Alliance and other revenuesalliance_and_other_revenues | $391m | $321m | — | $463m | +24.5% | — | |
| Cost of products sold (Non-GAAP)cost_of_products_sold_non_gaap | — | $3.41bn | $3.71bn | $4.13bn | +24.8% | +11.4% | |
| Net Earnings/(Loss)net_earnings | $1.09bn | — | $3.32bn | $2.16bn | −1.5% | −34.8% | |
| Other (income)/expense, net (Non-GAAP)other_income_expense_net_non_gaap | — | $173m | $126m | $93m | +145.1% | −26.2% | |
| Earnings/(Loss) before income taxes (Non-GAAP)pretax_income_non_gaap | — | $3.96bn | $4.99bn | $3.22bn | −24.4% | −35.5% | |
| Research and developmentrd_expense | — | $2.65bn | $2.96bn | $2.37bn | −6.4% | −20.1% | |
| Research and development (Non-GAAP)rd_expense_non_gaap | — | $2.24bn | $2.32bn | $2.36bn | −2.8% | +2.1% | |
| Selling, general and administrativesga_expense | — | $1.62bn | $1.83bn | $1.7bn | −5.0% | −7.0% | |
| Selling, general and administrative (Non-GAAP)sga_expense_non_gaap | — | $1.62bn | $1.83bn | $1.7bn | −5.0% | −7.0% | |
| Acquired IPRD Charges and Licensing Income Net Impact on Earnings/(Loss) Per Shareacquired_iprd_licensing_eps_impact | — | — | — | −$0.58 | −190.0% | — | |
| Alliance and other revenuesalliance_and_other_revenue | — | — | $385m | — | +6.9% | — | |
| Weighted-Average Common Shares Outstanding: Diluteddiluted_shares | — | 2,047 | — | — | +0.3% | — | |
| Gross profitgross_profit | $8.41bn | — | — | — | +11.6% | — | |
| Gross profit excluding specified itemsgross_profit_non_gaap | $8.99bn | — | — | — | −1.5% | — | |
| Income tax provision (Non-GAAP)income_tax_provision_non_gaap | — | $723m | — | — | +10.9% | — | |
| Acquired IPRD Charges and Licensing Income Net Impact on Earnings/(Loss) Per Shareiprd_licensing_eps_impact | — | −$0.03 | — | — | +25.0% | — | |
| Acquired IPRD Charges and Licensing Income Net Impact on Earnings/(Loss) Per Shareiprd_licensing_net_eps_impact | −$0.60 | — | — | — | −6100.0% | — | |
| Net Earnings/(Loss)net_income | — | $2.68bn | — | — | +8.8% | — | |
| Research and developmentresearch_and_development | $2.59bn | — | — | — | −19.0% | — | |
| Research and development excluding specified itemsresearch_and_development_non_gaap | $2.56bn | — | — | — | −8.1% | — | |
| Selling, general and administrativesga | $2.18bn | — | — | — | +2.1% | — | |
| Selling, general and administrative excluding specified itemssga_non_gaap | $2.09bn | — | — | — | −0.9% | — |
Segments
24 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Breyanzibreyanzi_revenue | $392m | $411m | $484m | $526m | +46.5% | +8.7% | |
| Camzyoscamzyos_revenue | $353m | $314m | $416m | $420m | +41.9% | +1.0% | |
| Cobenfycobenfy_revenue | $51m | $56m | $63m | $57m | +32.6% | −9.5% | |
| Eliquiseliquis_revenue | $3.45bn | $4.14bn | $4.48bn | $4.69bn | +25.2% | +4.7% | |
| Total Growth Portfoliogrowth_portfolio_revenue | $7.39bn | $6.23bn | $7.56bn | $7.66bn | +11.7% | +1.3% | |
| Total Revenues - Int'linternational_revenue | $3.94bn | $3.7bn | $3.98bn | $4bn | +2.6% | +0.3% | |
| Total Legacy Portfoliolegacy_portfolio_revenue | $5.11bn | $5.28bn | $5.42bn | $5.42bn | +0.9% | −0.1% | |
| Opdivoopdivo_revenue | $2.69bn | $2.15bn | $2.49bn | $2.37bn | −6.2% | −4.5% | |
| Opdualagopdualag_revenue | $350m | $295m | $349m | $367m | +22.7% | +5.2% | |
| Orenciaorencia_revenue | $1.01bn | $818m | $1.03bn | $983m | +2.0% | −4.9% | |
| Reblozylreblozyl_revenue | $666m | $555m | $735m | $750m | +22.0% | +2.0% | |
| Revlimidrevlimid_revenue | $602m | $349m | $425m | $303m | −47.3% | −28.7% | |
| Total Revenues - U.S.us_revenue | $8.56bn | $7.79bn | $8.99bn | $9.07bn | +8.9% | +0.9% | |
| Yervoyyervoy_revenue | $810m | $651m | $769m | $793m | +7.3% | +3.1% | |
| Abraxaneabraxane_revenue | — | $50m | $55m | $65m | −12.2% | +18.2% | |
| Krazatikrazati_revenue | — | $50m | $55m | $58m | +9.4% | +5.5% | |
| Opdivo Qvantigopdivo_qvantig_revenue | — | $163m | $261m | $334m | +398.5% | +28.0% | |
| Other Growth Productsother_growth_products_revenue | — | $581m | $653m | $731m | +12.3% | +11.9% | |
| Other Legacy Productsother_legacy_products_revenue | — | $156m | $170m | $154m | −13.0% | −9.4% | |
| Pomalyst/Imnovidpomalyst_revenue | $692m | $513m | $204m | — | −71.2% | −60.2% | |
| Sotyktusotyktu_revenue | — | $69m | $87m | $100m | +25.0% | +14.9% | |
| Sprycelsprycel_revenue | — | $73m | $88m | $73m | −38.7% | −17.0% | |
| Zeposiazeposia_revenue | — | $118m | $169m | $168m | +4.3% | −0.6% | |
| Pomalyst/Imnovidpomalyst_imnovid_revenue | — | — | — | $130m | −80.7% | — |
Margins
6 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Effective tax rateeffective_tax_rate | 26.2% | 17.3% | 18.8% | 14.8% | −49.8% | −21.3% | |
| Effective tax rate (Non-GAAP)effective_tax_rate_non_gaap | 22.1% | 18.3% | 16.5% | 14.1% | −36.8% | −14.5% | |
| Gross margingross_margin | 67.2% | 70.2% | 71.3% | 68.3% | −5.0% | −4.2% | |
| Gross margin (Non-GAAP)gross_margin_non_gaap | 71.9% | 70.3% | 71.4% | 68.4% | −6.2% | −4.2% | |
| Operating marginoperating_margin | 29.1% | — | — | — | +63.5% | — | |
| Operating margin excluding specified itemsoperating_margin_non_gaap | 34.8% | — | — | — | +1.5% | — |
Guided vs delivered
What the company told the market to expect, against what it then reported. Its own guidance is the only benchmark here — no analyst estimates appear anywhere on this site.
Data from company filings. Not investment advice.